Loading organizations...
§ Private Profile · Laguna Hills, CA, USA
clinical-stage biotechnology company developing URAT1 inhibitor treatments for gout and hyperuricemia to lower serum uric acid.
San Diego, California-based Arthrosi Therapeutics is a clinical-stage biotechnology company developing targeted treatments for metabolic diseases and gout, primarily focusing on its lead candidate AR882, a selective URAT1 inhibitor designed to reduce serum urate levels. The enterprise operates with a dedicated team of 15 employees and has raised $154 million in total funding to support its research and development pipeline. This capitalization includes a $75 million Series D financing round secured in July 2023 to advance its clinical trials and prepare for Phase 3 regulatory pathways with the United States FDA. The drug development firm is backed by a syndicate of institutional investors and strategic pharmaceutical partners, including recognizable entities such as Guangrun Health Industry, ApicHope Pharmaceuticals, and SR One. Arthrosi Therapeutics was officially founded in 2018 by Litain Yeh and Shunqi Yan.
Arthrosi Therapeutics has raised $243.0M across 3 funding rounds.
Arthrosi Therapeutics has raised $243.0M in total across 3 funding rounds.
Arthrosi Therapeutics has raised $243.0M across 3 funding rounds. Most recently, it raised $153.0M Series E in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 8, 2025 | $153M Series E | Prime Eight Capital | CR, HM Venture Partners, Relianttech | Announced |
| Jul 12, 2023 | $75M Series D | Guangrun Health Industry | Reichstein Biotech | Announced |
| Oct 23, 2020 | $15M Series C | — | — | Announced |
Arthrosi Therapeutics has raised $243.0M in total across 3 funding rounds.
Arthrosi Therapeutics's investors include Prime Eight Capital, Cr, HM Venture Partners, ReliantTech, Guangrun Health Industry, Reichstein Biotech.